Soraya Bekkali MD

Soraya is a board-certified MD graduated from Paris University specialized in Clinical Pharmacology and Biostatistics with 20 years of experience in Drug Development. She started her career in academia before joining the industry with Orphan Europe, in the rare disease space. She then joined Sanofi for 9 years where she held increasing leadership positions within global R&D, leading gene therapy programs in cardiovascular and Ophthalmology. She took over the leadership of the Ophthalmology Division in 2012 and in this capacity, drove Sanofi strategy towards ocular gene therapy efforts while setting up a multidisciplinary R&D and business organization.

Before joining Gyroscope mid-2017, Soraya served as SVP CMO at Lysogene, a biotech developing gene therapy treatment for rare CNS disorders. As a member of the executive team, she contributed to the successful listing of Lysogene on the European Stock Exchange Euronext. At Gyroscope, Soraya serves as CEO and CMO driving the company s strategy and operations in developing gene therapies for the treatment of eye diseases linked to an unbalanced Complement System.